Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06076304 · ClinicalTrials.gov registry record · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
A Phase 4 study of Sinus Infection and Acute Sinusitis, sponsored by Daniel Merenstein.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3,720
- Enrollment target
- 7
- Study locations
NCT06076304 is a Phase 4 study of Sinus Infection and Acute Sinusitis that is actively recruiting participants, run by Daniel Merenstein. The registered enrollment target is 3,720 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT06076304, a Phase 4 study of Sinus Infection and Acute Sinusitis, is actively recruiting participants, sponsored by Daniel Merenstein.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,720 participants
- Enrollment target
- 7
- Study locations
Study Summary
Sinus infections (also called acute rhinosinusitis or ARS) affect about 15% of adults each year, and are one of the top reasons people receive antibiotics in outpatient settings. Since most sinus infections are caused by viruses, many patients who take antibiotics for this condition do not actually benefit. Even though this has decreased over recent years, 70% of people are still prescribed them after a visit for ARS. Our goal is to better understand which patients truly benefit from antibiotics and which other treatment options can help people with sinus infections.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG amoxicillin/clavulanate potassium
- DRUG Budesonide nasal spray
Study Locations (7)
California
- University of California, Los Angeles - Los Angeles
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Maryland
- MedStar Health Research Institute - Hyattsville
Pennsylvania
- Penn State College of Medicine - Hershey
Virginia
- Virginia Commonwealth University - Richmond
Washington
- University of Washington - Seattle
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,720 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06076304
The ClinicalTrials.gov registry entry for NCT06076304 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 3,720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daniel Merenstein, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sinus Infection appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06076304 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06076304 about?
NCT06076304 is a clinical study titled "Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis". Sinus infections (also called acute rhinosinusitis or ARS) affect about 15% of adults each year, and are one of the top reasons people receive antibiotics in outpatient settings. Since most sinus infections are caused by viruses, many patients who take antibiotics for this condition do not actually ...
What is the current status of trial NCT06076304?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,720 participants. The study started on 2023-11-21. Estimated completion is 2028-12.
What conditions does trial NCT06076304 study?
This clinical trial studies the following conditions: Sinus Infection, Acute Sinusitis.
What interventions are being tested in trial NCT06076304?
The interventions under investigation include: Placebo (DRUG), amoxicillin/clavulanate potassium (DRUG), Budesonide nasal spray (DRUG).
Who is sponsoring clinical trial NCT06076304?
This trial is sponsored by Daniel Merenstein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06076304 being conducted?
This trial has 7 study locations across California, District of Columbia, Maryland, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.